Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma

Blood

Volumn 101, Issue 1, 2003, Pages 78-84

  Colomo, Lluís ^a,b   López Guillermo, Armando ^a,b,c   Perales, María ^a,b   Rives, Susana ^a,b   Martínez, Antonio ^a,b   Bosch, Francesc ^a,b   Colomer, Dolors ^a,b   Falini, Brunangelo ^a,b   Montserrat, Emili ^a,b   Campo, Elías ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF PERUGIA   (Italy)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD5 ANTIGEN; CD79A ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; PROTEIN; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN MUM1; PROTEIN P27; PROTEIN P53; SYNDECAN 1; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; BLAST CELL; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; GERMINAL CENTER; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; TUMOR DIFFERENTIATION;

EID: 0037217921     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-04-1286     Document Type: Article

References (48)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909-3918.
2. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412:341-346.
3. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
4. Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. WHO Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer (IARC) Press; 2001:171-174.
5. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
6. King BE, Chen C, Locker J, et al. Immunophenotypic and genotypic markers of follicular center cell neoplasia in diffuse large B-cell lymphoma. Mod Pathol. 2000;13:1219-1231.
7. Carbone A, Gaidano G, Gloghini A, et al. Differential expression of Bcl-6, CD138/Syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood. 1998;91:747-755.
8. Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and Bcl-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol. 2000;24:846-852.
9. Ree HJ, Yang WI, Kim CW, et al. Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: Significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma. Hum Pathol. 2001;32:954-962.
10. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood. 2002;99:1136-1143.
11. + groups may constitute clinically relevant subtypes. Leukemia. 1999;13:1441-1447.
12. Ohshima K, Kawasaki C, Muta H, et al. CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology. 2001;39:156-162.
13. Uherova P, Ross CW, Schnitzer B, Singleton TP, Finn WG. The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma. Am J Clin Pathol. 2001;115:582-584.
14. Lossos IS, Jones CD, Warnke R, et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood. 2001;98:945-951.
15. Alizadeh AA, Elsen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
16. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Med. 2002;8:68-74.
17. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
18. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood. 1996;87:265-272.
19. Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation study. Blood. 1996;88:1046-1051.
20. Kramer MH, Hemans J, Parker J, et al. Clinical significance of bcl-2 and p53 protein expression in diffuse large B-cell lymphoma: A population-based study. J Clin Oncol. 1996;14:2131-2138.
21. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 1997;90:244-251.
22. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL-2, BCL-6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998;92:3152-3162.
23. Tang SC, Visser L, Hepperle B, Hanson J, Poppema S, Clinical significance of bcl-2 MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: An analysis of 83 cases. J Clin Oncol. 1994;12:149-154.
24. Offit K, Lo Coco F, Louie DC, et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med. 1994;331:74-80.
25. Piris MA, Pezzella F, Martinez-Montero JC, et al. p53 and bcl-2 expression in high-grade B-cell lymphomas: Correlation with survival time. Br J Cancer. 1994;69:337-341.
26. Erlanson M, Portin C, Linderholm B, Lindh J, Roos G, Landberg G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas - Prognostic implications, Blood. 1998;92:770-777.
27. Ferreri AJM, Ponzoni M, Pruneri G, et al. Immunoreactivity for p27KIP1 and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin's lymphoma. Int J Cancer. 2001;94:599-604.
28. Saez A, Sanchez E, Sanchez-Beato M, et al. p27KIP1 is abnormally expressed in diffuse large B-cell lymphomas and is associated with an adverse clinical outcome. Br J Cancer. 1999;80:1427-1434.
29. Cheson BD, Horning SJ, Colffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:1244-1253.
30. Stansfeld AG, Diebold J, Kapanci Y, et al. Updated Kiel classification for lymphomas [letter]. Lancet. 1988;1:292-293.
31. Kaplan GL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
32. 2/E in the log-rank test for survival data or tumour incidence data. Biometrics. 1973;29:759-784.
33. Cox DR. Regression models and life tables. J R Stat Assoc. 1972;34:187-220.
34. Fang J-M, Finn WG, Hussong JW, Goolsby CL, Cubbon AR, Variakolis D. CD10 antigen expression correlates with the t(14;18)(q32;q21) major breakpoint region in diffuse large B-cell lymphoma. Mod Pathol. 1999;12:295-300.
35. Huang JZ, Sanger WG, Greiner TC, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood. 2002;99:2285-2290.
36. - diffuse large B-cell lymphoma. Am J Clin Pathol. 2001;116:183-190.
37. Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet. 1997;16:161-170.
38. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science. 1997;276:589-592.
39. Capello D, Vitolo U, Pasqualucci L, et al. Distribution and pattern of bcl-6 mutations throughout the spectrum of B-cell neoplasia. Blood. 2000;95:651-659.
40. Kawasaki C, Ohshlm K, Suzumiya J, et al. Rearrangements of bcl-1, bcl-2, bcl-6, and c-myc in diffuse large B-cell lymphomas. Leuk Lymphoma. 2001;42:1099-1106.
41. Grossman A, Mittrucker HW, Nocholl J, et al. Cloning of human lymphocyte-specific regulatory factor (hLSIRF/hIRF4) and mapping of the gene to 6p23-p25. Genomics. 1996;37:229-233.
42. Eisenbeis CF, Singh H, Storb U. Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator. Genes Dev. 1995;9:1377-1387.
43. Matsuyama T, Grossman A, Mittrucker HW, et al. Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). Nucleic Acids Res. 1995;23:2127-2136.
44. Yamagata T, Nishida J, Tanaka S, et al. A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. Mol Cell Biol. 1996;16:1283-1294.
45. Tsuboi K, lida S, Inagaki H, et al. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia. 2000;14:449-456.
46. Natkunam Y, Warnke RA, Montgomery K, Falini B, van de Rijn M. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol. 2001;14:686-694.
47. Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, and activated T cells. Blood. 2000;95:2084-2092.
48. Mittrucker HW, Matsuyama T, Grossman A, et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science. 1997;275:1075-1083.